Abstract
Nicotinic acetylcholine receptors are ligand-gated transmembrane ion channels that are present at the neuromuscular junction and in different locations in the nervous system. The different subtypes of neuronal nicotinic acetylcholine receptors that are found in the brain are thought to be involved in many neurological processes such as pain, cognitive function and depression, as well as in the pathophysiology of numerous neurological diseases and conditions. While the neurotransmitter acetylcholine is an endogenous agonist for all nicotinic receptors subtypes, many drugs that act as agonists and antagonists have also been identified or developed for these receptors. In addition, a novel class of compounds described as allosteric modulators have also been identified or developed for nicotinic acetylcholine receptors. Allosteric modulators are ligands that bind to nicotinic receptors at sites other than the orthosteric site where acetylcholine binds. One such allosteric modulator is desformylflustrabromine. Five chemical analogs along with desformylflustrabromine act as positive allosteric modulator for nAChRs that contain the beta2 subunit in their pentameric structure. Here the discovery and development, medicinal chemistry and pharmacological actions of desformylflustrabromine have been discussed. Desformylflustrabromine and its chemical analogs have the potential to develop into clinically used drugs for neurological diseases and conditions where nicotinic acetylcholine receptors are involved.
Keywords: Allosteric modulation, Desformylflustrabromine, functional effects, nicotinic acetylcholine receptor, positive allosteric modulators.
Current Pharmaceutical Design
Title:Desformylflustrabromine: A Novel Positive Allosteric Modulator for beta2 Subunit Containing Nicotinic Receptor Sub-Types
Volume: 22 Issue: 14
Author(s): Anshul A. Pandya
Affiliation:
Keywords: Allosteric modulation, Desformylflustrabromine, functional effects, nicotinic acetylcholine receptor, positive allosteric modulators.
Abstract: Nicotinic acetylcholine receptors are ligand-gated transmembrane ion channels that are present at the neuromuscular junction and in different locations in the nervous system. The different subtypes of neuronal nicotinic acetylcholine receptors that are found in the brain are thought to be involved in many neurological processes such as pain, cognitive function and depression, as well as in the pathophysiology of numerous neurological diseases and conditions. While the neurotransmitter acetylcholine is an endogenous agonist for all nicotinic receptors subtypes, many drugs that act as agonists and antagonists have also been identified or developed for these receptors. In addition, a novel class of compounds described as allosteric modulators have also been identified or developed for nicotinic acetylcholine receptors. Allosteric modulators are ligands that bind to nicotinic receptors at sites other than the orthosteric site where acetylcholine binds. One such allosteric modulator is desformylflustrabromine. Five chemical analogs along with desformylflustrabromine act as positive allosteric modulator for nAChRs that contain the beta2 subunit in their pentameric structure. Here the discovery and development, medicinal chemistry and pharmacological actions of desformylflustrabromine have been discussed. Desformylflustrabromine and its chemical analogs have the potential to develop into clinically used drugs for neurological diseases and conditions where nicotinic acetylcholine receptors are involved.
Export Options
About this article
Cite this article as:
Pandya A. Anshul, Desformylflustrabromine: A Novel Positive Allosteric Modulator for beta2 Subunit Containing Nicotinic Receptor Sub-Types, Current Pharmaceutical Design 2016; 22 (14) . https://dx.doi.org/10.2174/1381612822666160127113159
DOI https://dx.doi.org/10.2174/1381612822666160127113159 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Impact of Computer Science in Molecular Medicine: Enabling High- Throughput Research
Current Topics in Medicinal Chemistry Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine Design, Synthesis and Evaluation of 2,4,6-substituted Pyrimidine Derivatives as BACE-1 Inhibitor: Plausible Lead for Alzheimer’s Disease
Medicinal Chemistry Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Current Cancer Drug Targets Vitamin D and Subjective Memory Complaint in Community-Dwelling Older Adults
Current Alzheimer Research mGlu2/3 Agonist-Induced Hyperthermia: An In Vivo Assay for Detection of mGlu2/3 Receptor Antagonism and its Relation to Antidepressant-Like Efficacy in Mice
CNS & Neurological Disorders - Drug Targets Chronic Deposition of Aβ Influences Microcirculation in the Chronic Stage of Cerebral Ischemia
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Second Messenger Modulation: A Novel Target of Future Antidepressants?
Current Medicinal Chemistry Down Regulated Expression of Claudin-1 and Claudin-5 and Up Regulation of β-Catenin: Association with Human Glioma Progression
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Neuropharmacology Editorial [Hot Topic: Drug Discovery for CNS Disorders: From Bench to Bedside (Guest Editor: Tiago Fleming Outeiro)]
CNS & Neurological Disorders - Drug Targets A Case Presentation of Atypical X-linked Adrenoleukodystrophy: Initial Experience with ASL Technique
Current Medical Imaging Olfactory Ensheathing Cells Protect Cortical Neuron Cultures Exposed to Hypoxia
CNS & Neurological Disorders - Drug Targets Molecular Chaperone Activity and Biological Regulatory Actions of the TPR-Domain Immunophilins FKBP51 and FKBP52
Current Protein & Peptide Science Why do Psychotic Patients use Cannabis? Case Series
Current Pharmaceutical Design Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Utility of Mdr1-Gene Deficient Mice in Assessing the Impact of P-glycoprotein on Pharmacokinetics and Pharmacodynamics in Drug Discovery and Development
Current Drug Metabolism Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Neuroinflammation and its Modulation by Flavonoids
Endocrine, Metabolic & Immune Disorders - Drug Targets Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets